Serum omentin level in patients with prostate cancer

Medical Oncology

Volumn 31, Issue 4, 2014, Pages

  Uyeturk, Ugur ^a   Sarıcı, Hasmet ^b   Kın Tekce, Buket ^a   Eroglu, Muzaffer ^b   Kemahlı, Eray ^a   Uyeturk, Ummugul ^a   Gucuk, Adnan ^a  

^a ABANT IZZET BAYSAL UNIVERSITY   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Adipokine; Omentin; Prostate cancer

Indexed keywords

ADIPOCYTOKINE; CHOLESTEROL; CREATININE; LOW DENSITY LIPOPROTEIN; OMENTIN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; CYTOKINE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; ITLN1 PROTEIN, HUMAN; LECTIN;

ADULT; AGED; ARTICLE; BODY MASS; CANCER DIAGNOSIS; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLEASON SCORE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; ADIPOSE TISSUE; ANTHROPOMETRY; BIOPSY; BLOOD; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; PROSTATE; PROSTATE TUMOR; TREATMENT OUTCOME;

ADIPOSE TISSUE; ADULT; AGED; ANTHROPOMETRY; BIOPSY; BLOOD UREA NITROGEN; BODY MASS INDEX; CASE-CONTROL STUDIES; CHOLESTEROL; CREATININE; CYTOKINES; GENE EXPRESSION REGULATION, NEOPLASTIC; GPI-LINKED PROTEINS; HUMANS; LECTINS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84896413883     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0923-6     Document Type: Article

References (33)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29. doi: 10.3322/caac.20138.
2. Wilson KM, Giovannucci EL, Mucci LA. Lifestyle and dietary factors in the prevention of lethal prostate cancer. Asian J Androl. 2012;14(3):365-74. doi: 10.1038/aja.2011.142.
3. Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer. 1991;63(6):963-6.
4. Schmid HP, Engeler DS, Pummer K, Schmitz-Drager BJ. Prevention of prostate cancer: more questions than data. Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer. 2007;174:101-7.
5. Wuermli L, Joerger M, Henz S, Schmid HP, Riesen WF, Thomas G, et al. Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer Prostatic Dis. 2005;8(4):316-20. doi: 10.1038/sj.pcan.4500834.
6. Fair WR, Fleshner NE, Heston W. Cancer of the prostate: a nutritional disease? Urology. 1997;50(6):840-8. doi: 10.1016/s0090-4295(97)00339-7.
7. Freedland SJ, Giovannucci E, Platz EA. Are findings from studies of obesity and prostate cancer really in conflict? CCC. 2006;17(1):5-9. doi: 10.1007/s10552-005-0378-3.
8. De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes. 2013;2013:291546. doi: 10.1155/2013/291546.
9. Arisan ED, Arisan S, Atis G, Palavan-Unsal N, Ergenekon E. Serum adipocytokine levels in prostate cancer patients. Urol Int. 2009;82(2):203-8. doi: 10.1159/000200801.
10. Assadi M, Salimipour H, Akbarzadeh S, Nemati R, Jafari SM, Bargahi A, et al. Correlation of circulating omentin-1 with bone mineral density in multiple sclerosis: the crosstalk between bone and adipose tissue. PLoS ONE. 2011;6(9):e24240. doi: 10.1371/journal.pone.0024240.
11. Park J, Scherer PE. Adipocyte-derived endotrophin promotes malignant tumor progression. J Clin Investig. 2012;122(11):4243-56. doi: 10.1172/jci63930.
12. Alcelik A, Tosun M, Ozlu MF, Eroglu M, Aktas G, Kemahli E, et al. Serum levels of omentin in end-stage renal disease patients. Kidney Blood Press Res. 2012;35(6):511-6. doi: 10.1159/000338796.
13. Moreno-Navarrete JM, Ortega F, Castro A, Sabater M, Ricart W, Fernandez-Real JM. Circulating omentin as a novel biomarker of endothelial dysfunction. Obesity (Silver Spring, Md). 2011;19(8):1552-9. doi: 10.1038/oby.2010.351.
14. Tan BK, Adya R, Randeva HS. Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc Med. 2010;20(5):143-8. doi: 10.1016/j.tcm.2010.12.002.
15. Fazeli MS, Dashti H, Akbarzadeh S, Assadi M, Aminian A, Keramati MR, et al. Circulating levels of novel adipocytokines in patients with colorectal cancer. Cytokine. 2013;62(1):81-5. doi: 10.1016/j.cyto.2013.02.012.
16. Freedland SJ, Sokoll LJ, Platz EA, Mangold LA, Bruzek DJ, Mohr P, et al. Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy. J Urol. 2005;174(4 Pt 1):1266-70.
17. Li H, Stampfer MJ, Mucci L, Rifai N, Qiu W, Kurth T, et al. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem. 2010;56(1):34-43. doi: 10.1373/clinchem. 2009.133272.
18. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85-97. doi: 10.1038/nri2921.
19. Stattin P, Soderberg S, Hallmans G, Bylund A, Kaaks R, Stenman UH, et al. Leptin is associated with increased prostate cancer risk: a nested case-referent study. J Clin Endocrinol Metab. 2001;86(3):1341-5.
20. NCCN Guidelines Version 1.2014, Prostate Cancer. http://www.nccn.org/ professionals/physician-gls/pdf/prostate.pdf.
21. Berghofer A, Pischon T, Reinhold T, Apovian CM, Sharma AM, Willich SN. Obesity prevalence from a European perspective: a systematic review. BMC Public Health. 2008;8:200. doi: 10.1186/1471-2458-8-200.
22. Porter MP, Stanford JL. Obesity and the risk of prostate cancer. Prostate. 2005;62(4):316-21. doi: 10.1002/pros.20121.
23. Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2006;15(10):1977-83. doi: 10.1158/1055-9965.epi-06-0477.
24. Baillargeon J, Platz EA, Rose DP, Pollock BH, Ankerst DP, Haffner S, et al. Obesity, adipokines, and prostate cancer in a prospective population-based study. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2006;15(7):1331-5. doi: 10.1158/1055-9965.epi-06-0082.
25. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569-78. doi: 10.1016/s0140- 6736(08)60269-x.
26. Gapstur SM, Gann PH, Colangelo LA, Barron-Simpson R, Kopp P, Dyer A, et al. Postload plasma glucose concentration and 27-year prostate cancer mortality (United States). Cancer causes & control: CCC. 2001;12(8):763-72.
27. Tulinius H, Sigfusson N, Sigvaldason H, Bjarnadottir K, Tryggvadottir L. Risk factors for malignant diseases: a cohort study on a population of 22,946 Icelanders. Cancer Epidemiol Biomark Prev. 1997;6(11):863-73.
28. Albanes D, Weinstein SJ, Wright ME, Mannisto S, Limburg PJ, Snyder K, et al. Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst. 2009;101(18):1272-9. doi: 10.1093/jnci/djp260.
29. Hubbard JS, Rohrmann S, Landis PK, Metter EJ, Muller DC, Andres R, et al. Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging. Urology. 2004;63(2):253-8. doi: 10.1016/j.urology.2003.09.060.
30. Martinez-Garcia MA, Montes-Nieto R, Fernandez-Duran E, Insenser M, Luque-Ramirez M, Escobar-Morreale HF. Evidence for masculinization of adipokine gene expression in visceral and subcutaneous adipose tissue of obese women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab. 2013;98(2):E388-96. doi: 10.1210/jc.2012-3414.
31. de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes. 2007;56(6):1655-61. doi: 10.2337/db06-1506.
32. Choi JH, Rhee EJ, Kim KH, Woo HY, Lee WY, Sung KC. Plasma omentin-1 levels are reduced in non-obese women with normal glucose tolerance and polycystic ovary syndrome. Eur J Endocrinol. 2011;165(5):789-96. doi: 10.1530/eje-11-0375.
33. Zhang YY, Zhou LM. Omentin-1, a new adipokine, promotes apoptosis through regulating Sirt1-dependent p53 deacetylation in hepatocellular carcinoma cells. Eur J Pharmacol. 2013;698(1-3):137-44. doi: 10.1016/j.ejphar.2012.11.016.